(Date:3/12/2010)... College (BMCC) science major Kimberly Thompson wins $5,000 in CUNY ... ... York, NY (Vocus) March 12, 2010 -- Borough of ... won first place in the economics category of the 2009 ... Grand Prizewinner., , , , ,Thompson--the contest,s only awardee from ...
(Date:3/12/2010)... RESTATE EITHER DISCLOSURE OR ACCOUNTING TREATMENT , ... , , ... ... ... WA , March 12 /PRNewswire-FirstCall/ - Oncothyreon Inc. (Nasdaq: ONTY ) today announced that it will restate its 2008 financial statements contained in ...
(Date:3/11/2010)... Notice of Allowance of patent claims which strongly protects the formation of cartilage by the unique NELL 1 protein (UCB-1). Additional claims cover the surgical application ... ... , ... ... ...
(Date:3/11/2010)... agreement with Elan Pharmaceuticals, Inc. (a subsidiary of Elan Corporation, plc) ( ELN) ("Elan") to acquire the analgesic therapy, PRIALT(R) (ziconotide intrathecal infusion). , ... ... ... ... PRIALT is ...
Breaking Biology Technology:BMCC Student—the Only Community College Winner—Lands Grand Prize in Nobel Science Challenge 2Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 2Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 3Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 4Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 5Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 6Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 7Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 8Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 9Oncothyreon consults with Division of Corporation Finance about accounting for 2008 License Agreement 10Bone Biologics Announces a Major US Patent Issuance For Its Recombinant Protein Process For the Formation of Cartilage 2Bone Biologics Announces a Major US Patent Issuance For Its Recombinant Protein Process For the Formation of Cartilage 3Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 2Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 3Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 4Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 5Azur Pharma Announces the Signing of a Definitive Agreement to Acquire PRIALT(R) From Elan 6... , HIGHLIGHTS: 2008 Results (all percentage comparisons are to comparable periods in,2007):, ... Q1 2008 sales reached a new quarterly ... four business units also achieving new quarterly sales records and ... sales growth of 6.5% was enhanced by ...
... Inc. (NYSE: AOB ), a leading marketer, distributor ... that it plans to release first quarter 2008 financial ... The Company will hold a conference call on ... fiscal first quarter 2008 results. Listeners may access the,call ...
... Corporation (Nasdaq: ROCM ) will announce quarterly results ... Company will then,hold a quarterly conference call to discuss ... central daylight time (5:00 p.m. eastern time)., This ... accessed at,Rochester Medical,s website at http://www.rocm.com . To ...
Other Biology Technology:Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 2Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 3Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 4Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 5Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 6Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 7Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 8Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 9Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 10Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 11Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 12Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 13Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 14Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 15Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 16Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 17Sigma-Aldrich (Nasdaq: SIAL) Raises 2008 Diluted EPS Forecast by $.05 to $2.57-$2.67. Reports Q1 2008 Diluted EPS Up 14.3%; Sales Gain of 14.9%. 18American Oriental Bioengineering to Report First Quarter 2008 Financial Results 2Rochester Medical Announces Second Quarter 2008 Earnings Conference Call April 29, 2008 2... Stevens Institute of Technology has been awarded $1 ... support research and development into biomass conversion technologies. The ... to various higher-education institutions to develop their advanced biofuels ... $4.4 million in these university projects for their research ...
... skin disorder called vitiligo, which causes unsightly white patches on ... A Loyola University Hospital researcher has won a five-year, $1.7 ... vitiligo. This research also could point the way to new ... Vitiligo appears to be an auto-immune disease, in which the ...
... Center scientists have made a significant finding that could ... Huntington,s disease and Alzheimer,s disease. Compounds that block the ... greatly improved survival in fruit flies that had the ... were able to prevent Huntington,s disease-like illness in mutant ...
Other Biology News:Stevens awarded $1M for advanced biofuels research 2Vitiligo skin disorder could yield clues in fight against melanoma 2Duke team finds compounds that prevent nerve damage 2... Tissue Arrays are intended for laboratory research ... fixed in neutral buffered formalin and embedded ... was performed by certified pathologists. Tissue ... and relocated into a new recipient paraffin ...
... The kit contains all the reagents required ... NADPH-cytochrome c reductase activity in cell and ... reticulum (ER)]. It has been tested on ... liver, kidney, brain, spleen, and heart muscle ...
... pET Host Strain Competent Cell Sets ... vector/host strain combinations The most ... E. coli is to use ... be prepared in the laboratory, greater efficiency, ...
The Saturn 2200 answers your GC/MS questions with the CP-3800 GC and the 2000 Series Ion Trap MS! These components create a platform for the worlds most versatile GC and flexible MS. Both deliver une...
Biology Products:Biology NavigationMedical Navigation